Trial Profile
An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Cytarabine (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Idarubicin (Primary) ; Selinexor (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms FLAGINEXOR
- 01 Jun 2021 Results published in the Annals of Hematology
- 19 May 2020 Status changed from recruiting to completed.
- 17 Sep 2018 New trial record